Targeting the potential of PSMA

Telix’s prostate cancer portfolio targets PSMA (prostate-specific membrane antigen) – a protein that is overexpressed on the surface of prostate cancer cells and is low or absent on most normal healthy cells. PSMA has become a major breakthrough in the staging, treatment and management of prostate cancer, and the growing field of nuclear medicine.

High rates of screening in developed countries mean many men are diagnosed and treated early before their disease has spread. These men receive local therapy, either prostatectomy or EBRT, and may be cured of their disease. However, approximately 15% of patients develop advanced forms of the disease that can spread to other parts of the body. This is known as metastatic prostate cancer.

Imaging with targeted radiation can identify prostate cancer wherever it is in the body and help guide patient treatment.

Prostate cancer worldwide

1.4 million

estimated global incidence of prostate cancer in 2022


men died from prostate cancer globally in 2021


increase in prostate cancer diagnoses in Australia during the past 12 months


5-year survival rate for men diagnosed with early-stage prostate cancer in the United States